13F Holdings
中文EN

BDPT BIOADAPTIVES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%

Returns

ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$18,278$12,669$28,565$17,176$19,776
Cost of revenue$5,781$8,639$17,746$10,050$9,671
Gross profit$12,497$4,030$10,819$7,126$10,105
SG&A expense$820,508$335,306$101,478$254,119$268,268
Operating income-$1.04M-$602,090-$228,921-$421,900—
Interest expense$70,880$91,978$162,891$289,121$272,394
Pretax income-$1.56M-$899,161———
Income tax$0$0—$0$0
Net income-$1.56M-$899,161-$712,466-$895,570-$1.05M
EBITDA-$1.04M-$602,090———
EPS (basic)—-0.11-0.12——
EPS (diluted)-0.15-0.11———
Weighted avg. shares (diluted)10.07M8.22M———
Balance sheet
Cash & equivalents$158,445$137,470$60,776$25,405$82,936
Short-term investments$0$0$0$42$190
Inventory$44,706$19,115$15,281$8,877$4,750
Current assets$211,901$261,885$88,557$34,324$88,876
PP&E, net$14,000$0———
Intangibles$14,000$0$15,441$2,990—
Total assets$225,901$261,885$103,998$37,314$148,585
Current liabilities$2.36M$1.73M$1.75M$1.49M$1.24M
Total liabilities$2.36M$1.73M$1.75M$1.49M$1.24M
Shareholders' equity-$2.13M-$1.46M-$1.65M-$1.45M-$1.09M
Shares outstanding12.01M8.22M5.97M252.55M50.82M
Cash flow statement
Operating cash flow-$516,025-$249,517-$223,773-$227,259-$158,651
Capital expenditure$18,000$0———
Free cash flow-$534,025-$249,517———
Investing cash flow-$18,000$0———
Financing cash flow$555,000$326,211$259,144$169,728$237,000
Depreciation & amortization$4,000$0———
Stock-based compensation$28,670——$0$163,900

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.